MetaCap

Orchestra BioMed Holdings Inc. (OBIO)

NASDAQ: OBIOHealth Care Medicinal Chemicals and Botanical Products USD

6.58-0.42 (-6.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OBIO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$517.88M
EPS (TTM)
-$0.75
52-week range
3.46 – 7.83
Day range
6.47 – 7.14
Volume / Avg
554.32K / 420.19K
Beta
—

52-week range

$3.46$7.83

OBIO stock today

Orchestra BioMed (OBIO) closed at $6.58 on Nov 20, down 6.00% (-$0.42), versus the S&P 500's 3.70% decline. Shares are 15.9% below their 52-week high of $7.83, set on Nov 18, 2026 and 90.2% above the 52-week low of $3.46, in the middle of the past year's range. OBIO is up 58.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 45.3%.

Orchestra BioMed has posted a net loss over the last twelve months (EPS of -$0.75), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Orchestra BioMed

Company profile

Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease.

Industry
Medicinal Chemicals and Botanical Products
CEO
Mr. David P. Hochman
Headquarters
New Hope, PA
Employees
86
IPO year
2020

Financial highlights

Full financials

In fiscal 2025, Orchestra BioMed generated $33.5 million in revenue, up 1169.2% from fiscal 2024. Orchestra BioMed reported a net loss of $52.7 million, compared with a loss of $61.0 million a year earlier. Gross margin was 99.4% (up from 92.3%) and operating margin -154.7%.

Orchestra BioMed annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$33.48M$2.64M$2.76M$3.53M—
Growth+1169.22%-4.42%-21.88%——
Net income$-52.70M$-61.02M$-49.12M$-33.61M$-378.75K
EPS (diluted)$-1.11$-1.66$-1.48$-2.24$-0.02

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$13.29+101.98%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $10.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.30 vs $-0.40
Surprise
+25.00%

OBIO news

All OBIO news

Orchestra BioMed peers

Health Care sector
OBIO peer companies
CompanyPrice% ChgMarket capCompare
SNDLSNDL Inc.1.17-5.65%$285.20Mvs OBIO
TLRYTilray Brands Inc.1.89-8.70%$279.32Mvs OBIO
ACBAurora Cannabis Inc.4.16-2.35%$273.50Mvs OBIO
USNAUSANA Health Sciences Inc.12.94-1.67%$239.24Mvs OBIO
MDWDMediWound Ltd.13.59+0.37%$195.56Mvs OBIO
CGCCanopy Growth Corporation0.427-9.97%$191.99Mvs OBIO
NAGENiagen Bioscience Inc.1.84-1.60%$145.72Mvs OBIO
GLASGlass House Brands Inc. Subordinate Voting Shares1.18-2.48%$118.11Mvs OBIO

Indexes, lists and sector

Orchestra BioMed stock FAQ

What is Orchestra BioMed's stock price today?

OBIO last traded at $6.58 as of Nov 20, 4:00 PM EST, down 6.00% on the day. Prices are delayed at least 15 minutes.

Who is Orchestra BioMed's CEO?

Mr. David P. Hochman is the chief executive officer of Orchestra BioMed Holdings Inc., which has about 86 employees.

What is the OBIO 52-week high?

The 52-week high for OBIO is $7.83 and the 52-week low is $3.46. The stock is currently 15.9% below its high.

Compare OBIO